described (Nanus et al, 1990) . Polymerase chain reaction (PCR) was performed on DNA derived from the tumours using genespecific oligonucleotide primers as previously reported (Albino et al, 1991; Nanus et al, 1993a) . A single PCR product of 190 bp product was genotyped DD, of 490 bp product was genotyped II, and if both 190 bp and 490 bp were present the sample was genotyped DI (Rigat et al, 1990) . Any DNA sample genotyped DD underwent a second amplification with a nested primer to confirm the genotype (Shanmugan et al, 1993) . Amplification of the ACE gene used the following amplimers: sense 5′-CTGGAGAC-CACTCCCATCCTTTCT-3′ and anti-sense 5′-GATGTG-GCCATCACATTCGTCAGAT-3′ (Rigat et al, 1992) . The DD genotypes were confirmed using a nested sense primer 5′-TTTGA-GACGGAGTCTCGCTC-3′ as described (Shanmugan et al, 1993) . A χ 2 goodness of fit test was performed to determine if the observed proportion match with the control proportion (Armitage and Berry, 1987) . Two-sided P-values are reported.
RESULTS
DNA was extracted from normal kidney obtained at nephrectomy from 58 patients undergoing surgical resection of primary renal tumours. There were of 36 males and 22 females with a median age of 64 (range 32-83). Histological review revealed 46 clear cell carcinomas and 12 non-clear cell histologies (four papillary carcinomas, four chromophobe carcinomas, four oncocytomas). DNA was amplified using gene-specific primers for intron 16. Representative PCR results are illustrated in Figure 1 . The frequency of the ACE D and I alleles for all 58 patients was 0.612 and 0.388 respectively. This frequency was similar to that observed in a control population (Table 1 ). The observed frequencies of 0.362, 0.50 and 0.138 for the DD, DI and II genotypes respectively were not significantly different from the frequencies predicted by Hardy-Weinberg equilibrium (χ 2 = 2.01; P = 0.4). Subset analysis of the distribution of the D and I alleles in clearcell versus non-clear cell histology revealed a 75% incidence of the D allele in patients with non-clear cell renal tumours (χ 2 = 3.7, P = 0.06), however, there were only 12 samples in this cohort. 
DISCUSSION
The distribution of the ACE D and I alleles and the ACE genotypes in 58 patients diagnosed with renal cell carcinoma was similar to that observed in the normal population, and did not associate with the development of renal cancer. These data contrast multiple studies in which the DD polymorphism, which results in elevated plasma and membrane bound ACE, is associated with the development of benign renal diseases . Elevated ACE levels lead to increased angiotensin II production and bradykinin inactivation, and it is the increase in angiotensin II that is believed to contribute to the numerous pathological states associated with the DD genotype. Recent data indicate that angiotensin II functions at the cellular level as a growth factor (Wolf and Neilson, 1993; Wolf, 1995) and is essential for normal growth and development of renal tubules (Alcorn and Maric, 1996) . Despite that the current study which did not identify an increased frequency of the DD polymorphism does not implicate elevated ACE and consequently increased angiotensin II levels in the development of renal tumours, a number of recent studies do suggest that the renin-angiotensin system plays a role in renal carcinogenesis. Angiotensin II can induce the synthesis of basic fibroblast growth factor (bFGF) (Itoh et al, 1993) which has been implicated in the development and progression of renal cancers (Nanus et al, 1993b) . The ACE inhibitor Captopril significantly reduces the tumour size of renal cancer xenografts in athymic mice in a dose-dependent fashion (Hii et al, 1998) . We have shown that overexpression of aminopeptidase A, which converts angiotensin II to angiotensin III, in renal cancer cells inhibits anchorageindependent growth and tumorigenecity (unpublished data).
Finally, one recent study suggests that long-term use of ACE inhibitors may protect against cancer (Lever et al, 1998) . Taken together, these data begin to implicate ACE and its substrates including angiotensin II in the pathogenesis of renal cancers, and indicate that the involvement of the tissue renin-angiotensin system in this disease warrants further study. In summary, the distribution of the ACE polymorphism in 58 patients with renal cell carcinomas is not significantly different than the expected incidence in patients without renal cancers. These data suggest that elevated ACE levels do not predispose to the development of renal tumours. Further studies are needed to define the involvement of the renin-angiotensin system in renal carcinogenesis. Other population control as described (Schachter et al, 1994) .
